CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime–Avibactam And Aztreonam–Avibactam

References

• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.01331004767
   PubMed Web of Science ®Google Scholar
• Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(3):668–677. doi:10.1093/jac/dkw45927999023
   PubMed Web of Science ®Google Scholar
• Amit S, Mishali H, Kotlovsky T, Schwaber MJ, Carmeli Y. Bloodstream infections among carriers of carbapenem-resistant klebsiella pneumoniae: etiology, incidence and predictors. Clin Microbiol Infect. 2015;21(1):30–34. doi:10.1016/j.cmi.2014.08.00125636924
   PubMed Web of Science ®Google Scholar
• Márió G. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892. doi:10.3390/molecules24050892
   Web of Science ®Google Scholar
• Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272. doi:10.1016/j.molmed.2012.03.00322480775
   PubMed Web of Science ®Google Scholar
• Lutgring JD, Limbago BM. The problem of carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. J Clin Microbiol. 2016;54(3):529–534. doi:10.1128/JCM.02771-1526739152
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663. doi:10.1128/AAC.01222-1324080646
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. In vitro activity of aztreonam-avibactam against a global collection of gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015;59(7):4239–4248. doi:10.1128/AAC.00206-1525963984
   PubMed Web of Science ®Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw23927432599
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443–e01517. doi:10.1128/AAC.01443-1728848018
   PubMed Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00642–e00717. doi:10.1128/AAC.00642-1728630202
   PubMed Web of Science ®Google Scholar
• Monogue ML, Thabit AK, Hamada Y, Nicolau DP. Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother. 2016;60(8):5001–5005. doi:10.1128/AAC.00366-1627353265
   PubMed Web of Science ®Google Scholar
• Denervaud-Tendon V, Poirel L, Connolly LE, Krause KM, Nordmann P. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother. 2017;72(10):2787–2791. doi:10.1093/jac/dkx23929091226
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968–17. doi:10.1128/AAC.01968-1729158270
   PubMed Web of Science ®Google Scholar
• Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257–264. doi:10.1093/cid/ciw74128013264
   PubMed Web of Science ®Google Scholar
• Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615–628. doi:10.1007/s40265-017-0725-128303449
   PubMed Web of Science ®Google Scholar
• Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane/ tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74(2):380–386. doi:10.1093/jac/dky42530357343
   PubMed Web of Science ®Google Scholar
• Emeraud C, Escaut L, Boucly A, et al. Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-beta-lactamase-producing gram-negative bacteria. Antimicrob Agents Chemother. 2019;63(5):e00010–19. doi:10.1128/AAC.00010-1930858212
   PubMed Web of Science ®Google Scholar
• Hobson CA, Bonacorsi S, Fahd M, et al. Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. Antimicrob Agents Chemother. 2019;63(2). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205. doi:10.1093/cid/ciy66030423057
   PubMed Web of Science ®Google Scholar
• Tian X, Sun S, Jia X, Zou H, Li S, Zhang L. Epidemiology of and risk factors for infection with extended-spectrum beta-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case-control study. Infect Drug Resist. 2018;11:1339–1346. doi:10.2147/IDR.S17345630214254
   PubMed Web of Science ®Google Scholar
• French CE, Coope C, Conway L, et al. Control of carbapenemase-producing Enterobacteriaceae outbreaks in acute settings: an evidence review. J Hosp Infect. 2017;95(1):3–45. doi:10.1016/j.jhin.2016.10.00627890334
   PubMed Web of Science ®Google Scholar
• Li X, Ye H. Clinical and mortality risk factors in bloodstream infections with carbapenem-resistant Enterobacteriaceae. Can J Infect Dis Med Microbiol. 2017;2017:6212910. doi:10.1155/2017/621291029379527
   PubMed Web of Science ®Google Scholar
• Sousa A, Perez-Rodriguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170–3175. doi:10.1093/jac/dky29530099490
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x29671219
   PubMed Web of Science ®Google Scholar
• Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243–16. doi:10.1128/AAC.02243-1628167541
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62:5. doi:10.1128/AAC.02497-17
   Web of Science ®Google Scholar
• Shen Z, Ding B, Ye M, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72(7):1930–1936. doi:10.1093/jac/dkx06628333323
   PubMed Web of Science ®Google Scholar
• Nelson K, Hemarajata P, Sun D, et al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother. 2017;61(10):e00989–17. doi:10.1128/AAC.00989-1728739787
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–17. doi:10.1128/AAC.02101-1729263067
   PubMed Web of Science ®Google Scholar
• Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother. 2018;62(1):e01970–17.29133568
   PubMed Web of Science ®Google Scholar
• Alm RA, Johnstone MR, Lahiri SD. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother. 2015;70(5):1420–1428. doi:10.1093/jac/dku56825634992
   PubMed Web of Science ®Google Scholar